Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
- PMID: 22361010
- PMCID: PMC3308210
- DOI: 10.1186/1741-7015-10-20
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD. The LRRK2 protein contains a central catalytic region, and pathogenic mutations cluster in the Ras of complex protein C terminus of Ras of complex protein (mutations N1437H, R1441G/C and Y1699C) and kinase (G2019S and I2020T) domains. Much attention has been focused on the kinase domain, because kinase-dead versions of mutant LRRK2 are less toxic than kinase-active versions of the same proteins. Furthermore, kinase inhibitors may be able to mimic this effect in mouse models, although the currently tested inhibitors are not completely specific. In this review, we discuss the recent progress in the development of specific LRRK2 kinase inhibitors. We also discuss non-kinase-based therapeutic strategies for LRRK2-associated PD as it is possible that different approaches may be needed for different mutations.
Figures

Similar articles
-
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.ACS Chem Neurosci. 2012 Mar 21;3(3):151-60. doi: 10.1021/cn200117j. Epub 2012 Jan 18. ACS Chem Neurosci. 2012. PMID: 22860184 Free PMC article. Review.
-
Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.Sci Transl Med. 2012 Dec 12;4(164):164ra161. doi: 10.1126/scitranslmed.3004485. Sci Transl Med. 2012. PMID: 23241745
-
Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Expert Opin Ther Pat. 2012 Dec;22(12):1415-26. doi: 10.1517/13543776.2012.729041. Epub 2012 Nov 6. Expert Opin Ther Pat. 2012. PMID: 23126385 Review.
-
Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).Expert Opin Ther Pat. 2014 Jul;24(7):745-57. doi: 10.1517/13543776.2014.907275. Epub 2014 Jun 11. Expert Opin Ther Pat. 2014. PMID: 24918198 Review.
-
Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.Curr Top Med Chem. 2015;15(10):927-38. doi: 10.2174/156802661510150328223655. Curr Top Med Chem. 2015. PMID: 25832719 Review.
Cited by
-
Lrrk2 modulation of Wnt signaling during zebrafish development.J Neurosci Res. 2020 Oct;98(10):1831-1842. doi: 10.1002/jnr.24687. Epub 2020 Jul 5. J Neurosci Res. 2020. PMID: 32623786 Free PMC article.
-
LRRK2 regulation of immune-pathways and inflammatory disease.Biochem Soc Trans. 2019 Dec 20;47(6):1581-1595. doi: 10.1042/BST20180463. Biochem Soc Trans. 2019. PMID: 31769472 Free PMC article. Review.
-
Emerging preclinical pharmacological targets for Parkinson's disease.Oncotarget. 2016 May 17;7(20):29835-63. doi: 10.18632/oncotarget.8104. Oncotarget. 2016. PMID: 26988916 Free PMC article. Review.
-
Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).Stem Cell Res. 2021 May;53:102354. doi: 10.1016/j.scr.2021.102354. Epub 2021 Apr 15. Stem Cell Res. 2021. PMID: 34087985 Free PMC article.
-
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).Leukemia. 2014 Feb;28(2):404-7. doi: 10.1038/leu.2013.205. Epub 2013 Jul 4. Leukemia. 2014. PMID: 23823659 No abstract available.
References
-
- Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R. et al.Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308–1312. doi: 10.1038/ng.487. - DOI - PMC - PubMed
-
- International Parkinson Disease Genomics Consortium. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641–649. - PMC - PubMed
-
- Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Züchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Pericak-Vance M, Haines J, Vance JM, Martin ER. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74:97–109. doi: 10.1111/j.1469-1809.2009.00560.x. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical